DAFTAR PUSTAKA


8. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010


19. World Health Organization , WHO Case Definitions of HIV and Revised Clinical Staging and Immunological Classification of HIV-related disease in Adult and Children, 2007b


29. Raoul Moh, Christine Danel. Haematological changes in adults receiving a 
zidovudine-containing HAART regimen in combination with cotrimoxazole 
in Cote d'Ivoire, Antiviral Therapy 10:615–624. 2002
30. Surendra K. Sharma, Zidovudine-induced anaemia in HIV/AIDS. Indian J 
Med Res 132, October 2010, pp 359-361
31. Moyle G. Anaemia in persons with HIV infection: prognostic marker and 
contributor to morbidity. AIDS Reviews. 2002;4:13-20
32. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, 
Leedom JM, Groopman JE, Mildvan D & Hirch MS. The toxicity of 
azidothymidine (AZT) in the treatment of patients with AIDS and AIDS 
related complex. A double-blind placebo-controlled trial. New England 
Journal of Medicine 1987;317:192-197
33. SE Huffam, P Srasuebkul, Prior antiretroviral therapy experience protects 
against 
zidovudine-related anaemia, on behalf of The TREAT Asia 
34. S. Takuva, G. Louwagie, K. Zuma, and V. Okello, “Durability of first line 
antiretroviral therapy: reasons and predictive factors for modifications in 
a Swaziland Cohort,” Journal of Antivirals and Antiretrovirals, vol. 4, no. 1, 
35. Kavindhran Velen, James J. Lewis, Comparison of Tenofovir, Zidovudine, 
or Stavudine as Part of First-Line Antiretroviral Therapy in a Resource-
Limited-Setting: A Cohort Study; PLOS ONE, www.plosone.org 1 May 
2013, Volume 8, Issue 5.